newwin
Luciann Nguyen
Settings
← Accounts
biotech

Sichuan Huiyu Pharmaceutical Co., Ltd

50
Account opportunity
Not established
Relationship
1
Active signals
1
Trials as sponsor

Why this account matters

Sichuan Huiyu Pharmaceutical Co., Ltd

New trial — Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation

New trialNCT06243354
50/100
Opportunity
Commercial fit6/25
Clinical timing20/20
Biomarker need5/20
Relationship2/10
Signal strength9/10
Account value7/10
Urgency1/5

New phase 1_2 trial NCT06243354 posted by Sichuan Huiyu Pharmaceutical Co., Ltd: "Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation". New trial on a phase 1_2 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 222 days ago.

ConfidenceHigh · 87%clinical development · translational medicine · clinical operations
Draft outreachReview

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

TrialPhaseTesting language
NCT06243354
Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation
phase 1 2
mol. elig.